Legg Mason Global Infrastructure ETF

Most Recent

  • uploads///AdobeStock_

    Will Genocea Stock Bounce Back? In-Depth Analysis

    Today, we’re taking a close look at Genocea (GNCA) to show why the stock could bounce back after fluctuating significantly over the last year.

    By Oleksandr Pylypenko
  • uploads///Graph
    Company & Industry Overviews

    Comparing Revenue Growth Trends for AMRN and IOVA

    In its first-quarter earnings conference call, Amarin (AMRN) reiterated its fiscal 2019 net revenue guidance of $350 million, which represents a YoY rise of more than 50%.

    By Margaret Patrick
  • uploads///fish oil _
    Company & Industry Overviews

    What Are Analysts Recommending for AMRN and IOVA in May?

    The consensus recommendation for Amarin in May is a “strong buy,” while the consensus recommendation for Iovance Biotherapeutics is a “buy.”

    By Margaret Patrick
  • uploads///Mirati
    Company & Industry Overviews

    Mirati Therapeutics Stock Has Delivered Solid Growth in 2018

    On November 21, Mirati Therapeutics (MRTX) stock closed at $40.24, a ~2.57% fall from its previous day’s close of $41.30.

    By Daniel Collins
  • uploads///entrepreneur _
    Company & Industry Overviews

    Iovance Biotherapeutics: The News That Drove Up the Stock

    On October 12, Iovance Biotherapeutics (IOVA) stock rose 19.66% to $11.93 after the announcement of the price for its public offering.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.